Foundayo vs Wegovy Pill for Weight Loss

Both Foundayo and the Wegovy pill have U.S. Food and Drug Administration (FDA) approval as oral glucagon-like peptide-1 (GLP-1) medicines for weight management.^1,2 OASIS 4 found an average body-weight change of −13.6% at week 64 with oral semaglutide versus −2.2% with placebo.³ ATTAIN-1 found −11.2% at week 72 with the highest orforglipron dose studied versus −2.1% with placebo.⁴ No head-to-head trial has compared the pills. The Wegovy label sets an empty-stomach morning routine with a wait, while Foundayo can be taken with or without food.^1,2

Side-by-Side Foundayo vs Wegovy Pill Comparison

The Foundayo vs Wegovy pill choice depends on more than the average weight change from each trial. The labels differ in administration, indications, drug structure, and starting self-pay price.

A headline percentage leaves out what is driving your weight. A physician can examine hormones, insulin, sleep, eating habits, exercise, and stress before matching a prescription to your history and routine.

	Wegovy pill	Foundayo
Active ingredient	Semaglutide	Orforglipron
Molecule type	Peptide GLP-1 receptor agonist	Nonpeptide small-molecule GLP-1 receptor agonist
Manufacturer	Novo Nordisk	Eli Lilly and Company
FDA approval (date and source)	December 22, 2025, according to Novo Nordisk6	April 1, 2026, according to Eli Lilly7
Label weight-management indication	Long-term weight reduction for adults with obesity, or overweight with at least one weight-related condition1	Long-term weight reduction for adults with obesity, or overweight with at least one weight-related condition2
Additional label indication	Reduces the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight1	No additional indication beyond weight management is listed2
What the label requires for taking it	Once daily in the morning on an empty stomach with water only, followed by a wait of at least 30 minutes before food, beverages, or other oral medicines1	Once daily with or without food. The tablet is swallowed whole.2
Main weight trial and length	OASIS 4, weight endpoint at week 64, 307 participants3	ATTAIN-1, 72 weeks, 3,127 participants4
Average weight change in that trial (vs placebo)	−13.6% vs −2.2% at week 643	−11.2% vs −2.1% at week 72 with the highest dose studied4
Most common side effects	Gastrointestinal events occurred in 74.0% of the oral semaglutide group and 42.2% of the placebo group in OASIS 43	Nausea, constipation, diarrhea, and vomiting were the most common adverse reactions2
Stopped for adverse events in the trial	6.8% with the Wegovy pill and 5.9% with placebo1	5.3% to 10.3% across orforglipron groups and 2.7% with placebo4
Self-pay starting price (source, read date)	Starting at $149 per month through NovoCare Pharmacy, read September 15, 20268	Starting at $149 per month through Lilly’s Foundayo coverage and savings page, read September 15, 20269
Verdict	A physician may favor Wegovy when its cardiovascular indication fits your history and the morning routine is workable.	A physician may favor Foundayo when flexible timing fits your routine, after reviewing other oral medicines and tolerability.

Your physician reads those two averages against your cardiovascular history, other medicines, and routine.

Reading the OASIS 4 and ATTAIN-1 Results

OASIS 4 and ATTAIN-1 studied different populations over different periods. OASIS 4 enrolled 307 adults without diabetes who had obesity or overweight with at least one obesity-related complication.³ Its primary weight endpoint was measured at week 64.

ATTAIN-1 enrolled 3,127 adults with obesity and without diabetes. Participants received orforglipron or placebo alongside diet and physical activity for 72 weeks.⁴ The highest dose studied produced an average body-weight change of −11.2%, compared with −2.1% for placebo.

The sample-size gap is large. The Wegovy result came from 307 participants, while the Foundayo result came from 3,127 participants. The studies also differed in eligibility criteria and duration. Comparing −13.6% with −11.2% as if both numbers came from the same experiment ignores those differences.

Your health profile affects how closely either trial applies. If you have overweight with a related medical condition, the OASIS 4 population may resemble your situation more closely. If you have obesity without diabetes, both populations may be relevant. Neither average directly represents adults with diabetes because both trials excluded them.^3,4

Trial averages also do not predict your personal result or provide a timeline for reaching a specific weight. Your physician has to read the percentages alongside your medical history, starting weight, response, and ability to remain on treatment.

The Population-Adjusted Indirect Comparison

The Michalak 2026 indirect comparison favored oral semaglutide under one specified statistical method. Michalak et al. adjusted the OASIS 4 population to compare it with aggregate data from ATTAIN-1.⁵ The analysis estimated 3.2 percentage points more weight loss with oral semaglutide under the treatment-regimen estimand, with a 95% confidence interval from 0.4 to 5.9 percentage points in its favor.

The analysis also associated oral semaglutide with fewer discontinuations from any adverse event and from gastrointestinal adverse events.⁵ It remains an indirect comparison. Participants were never randomized between Wegovy pill and Foundayo inside one trial.

Funding affects how the result should be read. Five authors were Novo Nordisk employees and shareholders, and two worked for a firm Novo Nordisk paid to support the study.⁵ The statistical result belongs in the comparison, but it does not settle which pill will work better or feel easier for you to take. Your physician weighs it alongside your cardiovascular history, other oral medicines, and how you tolerate escalation.

Morning Routines and Other Oral Medicines

The administration routine is the clearest label difference between the pills. The Wegovy pill label requires morning use on an empty stomach with water only. It also requires a wait of at least 30 minutes before food, other drinks, or oral medicines.¹ Your prescriber or pharmacist explains how that routine fits with your other prescriptions.

The Foundayo label allows once-daily use with or without food.² Eli Lilly also describes Foundayo as having no food or water restrictions.⁷ That flexibility may be useful if your mornings change from day to day.

Other oral medicines still require review with either choice. Foundayo delays gastric emptying and may affect the absorption of oral medicines taken alongside it.² A physician and pharmacist can review timing, monitoring needs, and whether another prescription requires closer attention.

If you take several morning medicines, the Wegovy waiting period may add complexity. If your work, travel, or family schedule makes a fixed morning routine difficult, Foundayo may be easier to use consistently. Convenience does not determine clinical fit by itself, but a routine you can maintain belongs in the prescribing decision.

Each label provides a fixed regimen, but your prescribing plan should be personalized. Your history, medication list, and daily schedule inform the initial choice, and follow-up can change it.

Questions about the tablet and weekly pen belong in the Wegovy pill versus injection comparison.

Cardiovascular History in the Choice

The Wegovy pill has an additional cardiovascular indication that Foundayo does not carry. The Wegovy tablet label includes risk reduction for cardiovascular death, nonfatal heart attack, or nonfatal stroke in adults with established cardiovascular disease and obesity or overweight.¹

If you have established cardiovascular disease, your physician may give that indication added weight. It provides a label-based reason to consider Wegovy beyond body-weight change. It does not establish that Wegovy is the better pill for every person with cardiovascular risk factors.

Foundayo is approved for long-term weight management in qualifying adults.² Its label does not include the same cardiovascular risk-reduction indication. Your cardiovascular history therefore changes the comparison even when both pills fit the weight-management indication.

Tolerability Across Separate Trials

Gastrointestinal symptoms were the main tolerability issue with both medicines. In OASIS 4, gastrointestinal adverse events occurred in 74.0% of participants receiving oral semaglutide and 42.2% receiving placebo.³ Adverse reactions led 6.8% of Wegovy tablet participants and 5.9% of placebo participants to stop treatment.¹

Across the three Foundayo maintenance strengths studied in its safety pool, gastrointestinal adverse reactions occurred in 60% to 69% of participants, compared with 37% receiving placebo.² Nausea occurred in 26% to 35%, constipation in 20% to 27%, diarrhea in 21% to 25%, and vomiting in 13% to 24%. Foundayo’s label states that nausea, vomiting, and diarrhea occurred more often during dosage escalation and decreased over time.²

These percentages cannot be used to declare one pill easier to tolerate. The Wegovy and Foundayo rates came from different trials and safety pools. Participant characteristics, follow-up, escalation, and adverse-event collection can change the reported rates.

Your prior experience with GLP-1 treatment can carry more weight than a cross-trial percentage. If one medicine produces symptoms that prevent you from eating adequately or staying on treatment, your prescriber may slow the plan, reassess the prescription, or consider the other pill. A real tolerability problem can change the choice even when the first prescription looked better on paper.

Physician Factors for Choosing a Pill

A physician chooses between these pills by combining the labels with your health history and daily routine. The main considerations include established cardiovascular disease, other oral medicines, schedule consistency, prior gastrointestinal symptoms, and response during escalation.

A comprehensive baseline adds context beyond the label and trial average. Opt Health uses 55+ biomarkers spanning hormones, inflammation, cardiovascular risk, and more, followed by a 1:1 physician review.

Both labels contraindicate use in people with a personal or family history of medullary thyroid carcinoma (MTC) and in people with multiple endocrine neoplasia syndrome type 2 (MEN 2).^1,2 If either applies to you, your physician will consider another treatment. Foundayo’s label also states that use with another GLP-1 receptor agonist is not recommended.²

For current self-pay details across strengths, use the GLP-1 cost guide when you and your physician weigh cost. Published starting prices can look identical while the ongoing price differs by prescribed strength and program terms.^8,9

A future randomized head-to-head trial could change the comparison. A tolerability problem on either prescription can also change the choice for you. Until direct evidence exists, the best GLP-1 pill is the one your physician can match to your diagnosis, other medicines, cardiovascular history, and routine.

The Opt Take on Foundayo vs Wegovy Pill

Opt Health starts with physician interpretation before any GLP-1 prescription. A physician reads your labs against your health history, current medications, routine, and goals, then builds a plan around that full picture. The choice between Foundayo and the Wegovy pill follows your numbers and clinical fit. A trial average cannot make that decision for you.

Your baseline includes 55+ biomarkers collected at home or at a local partner lab. A 1:1 physician review looks across hormones, inflammation, cardiovascular risk, and other results for a pattern. The physician can then consider the label indications, your morning routine, other oral medicines, and prior tolerability.

Labs and a physician consultation repeat every 3 to 4 months. Your measured response gives the physician new information for adjusting the plan, including whether the drug or form still fits. Prescriptions can be shipped from our pharmacy as part of treatment, and membership is required to receive treatment. The GLP-1 guide for men explains how treatment fits into a broader physician-led weight plan.

Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.

Frequently Asked Questions

Self-pay prices and offer terms can change without notice. Verify current figures on the NovoCare Wegovy pricing page and the Lilly Foundayo coverage page before relying on them.

This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.